Merck Foundation
Merck & Co., Inc. is a publicly traded research-intensive biopharmaceutical company developing prescription medicines, vaccines, and animal health products across oncology, infectious disease, cardiometabolic, and neuroscience franchises, serving healthcare providers and patients globally through direct sales, distributor networks, and patient assistance programs.
- Company typePublic
- Founded1891
- HeadquartersRahway, United States
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What Merck Foundation does
Merck & Co., Inc. (operating as Merck in the United States, Canada and Puerto Rico, and as MSD in all other markets) is a publicly traded research-intensive biopharmaceutical company founded in 1891 and headquartered in Rahway, New Jersey. The company develops, manufactures, and commercializes prescription pharmaceuticals, vaccines, and animal health products across therapeutic areas including oncology, vaccines, infectious diseases, cardiometabolic and respiratory conditions, immunology, neuroscience, and ophthalmology. Flagship oncology asset KEYTRUDA (pembrolizumab), a PD-1 inhibitor, anchors the portfolio alongside vaccines GARDASIL 9, CAPVAXIVE, VAXNEUVANCE, and ERVEBO; infectious disease products LAGEVRIO, ZEPATIER, PREVYMIS, and ISENTRESS; cardiometabolic/respiratory products JANUVIA, WINREVAIR, OHTUVAYRE, and VERQUVO; and animal health products BRAVECTO and Activyl through the Merck Animal Health subsidiary. R&D operations span multiple modalities — small molecules, biologics, antibody-drug conjugates, individualized neoantigen therapies — supported by data science and AI platforms including the proprietary KERMT small-molecule lead optimization model and multimodal AI agents for drug discovery.
Merck generates revenue primarily through prescription pharmaceutical and vaccine sales via three channels: direct field sales to healthcare providers and hospitals, distribution through authorized distributor and pharmacy networks globally, and direct patient access through the MerckHelps patient assistance program. The company holds an extensive granted U.S. patent portfolio protecting its major franchises and markets through physician engagement, patient support programs, scientific conferences, and digital content including podcasts and clinical trial information. Beyond commercial operations, Merck operates the Merck for Mothers global initiative — launched in 2011 with a $500M commitment extended by an additional $150M through 2025 — that has reached 30M+ women across 75+ country sites through partnerships with organizations including PATH, Jhpiego India, FOGSI, City Cancer Challenge, Global Financing Facility, and the CDC.
Merck Foundation firmographics
Firmographics- Name
- Merck Foundation
- Legal name
- Merck & Co., Inc.
- Website
- https://merck.com
- Company type
- Public
- Founded year
- 1891
- Operating status
- Operating
- Short description
- Merck & Co., Inc. is a publicly traded research-intensive biopharmaceutical company developing prescription medicines, vaccines, and animal health products across oncology, infectious disease, cardiometabolic, and neuroscience franchises, serving healthcare providers and patients globally through direct sales, distributor networks, and patient assistance programs.
- Ownership category
- akta.pro rank
Merck Foundation industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
- akta.pro secondary industries
- Monitoring, Evaluation, Research & Learning (MERL) (BPAGABAO), Travel & Tropical Disease Vaccines (HLAIAEAE)
Keywords
Where Merck Foundation is headquartered
LocationHeadquarters
- HQ city
- Rahway
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Merck Foundation business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Pharmaceutical Products: Revenue generated from prescription medicines and vaccines sold to healthcare providers, hospitals, pharmacies, and directly to patients through patient assistance programs. Products include KEYTRUDA, vaccines, and treatments across multiple therapeutic areas.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Merck Patient Assistance Program |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels7 records
Merck Foundation product offering
Product offeringCore offering
Merck & Co., Inc. is a research-intensive biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines, vaccines, and animal health products across oncology, infectious diseases, vaccines, cardiometabolic diseases, immunology, and rare diseases. The company's flagship products include KEYTRUDA (pembrolizumab), GARDASIL 9, CAPVAXIVE, LAGEVRIO, and WINREVAIR. It also runs the Merck for Mothers global initiative to end preventable maternal deaths.
Product overview
Merck & Co., Inc. (known as Merck Foundation in the US context) is a premier research-intensive biopharmaceutical company with a diversified portfolio of prescription pharmaceuticals, vaccines, and animal health products. The company operates across multiple therapeutic areas including oncology (KEYTRUDA), vaccines (GARDASIL 9, CAPVAXIVE, VAXNEUVANCE, ERVEBO), infectious diseases, cardiometabolic diseases, and immunology. Merck for Mothers represents the company's global social impact initiative focused on maternal health. The portfolio spans from innovative cancer immunotherapies to preventive vaccines and treatments for chronic conditions, supported by extensive R&D capabilities in data science, AI, and drug discovery.
Differentiator
Problem solved
Functional benefit
Brands
- Merck for Mothers: Global initiative to help create a world where no woman has to die while giving life, focused on advancing high-quality maternity care, harnessing innovations for maternal health, and catalyzing solutions that respond to local needs
- Merck Animal Health
- MSD
Quantifiable outcome
- 30+ million women reached with maternal health programs
- +2 more outcomes
Companies that use Merck Foundation
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles4 records
Merck Foundation technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature11 records
Merck Foundation partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- City Cancer ChallengecoreMerck and City Cancer Challenge expanded global partnership to strengthen women's cancer care. The initiative aims to reach more than 300,000 women living with cancer around the world by 2030 through collaborative programs addressing cancer diagnosis, treatment, and care access.
- CDC (Centers for Disease Control and Prevention)coreMerck for Mothers provided funding to support CDC's Hear Her maternal health communication campaign, bringing attention to maternal mortality and providing support to pregnant and postpartum women.
- Jhpiego IndiacoreMerck for Mothers partnered with Jhpiego India and the Federation of Obstetric and Gynecological Societies of India to launch Manyata - an initiative to improve quality maternity and newborn care in private facilities through training on clinical, facility, and patient care protocols.
- Federation of Obstetric and Gynecological Societies of IndiacorePartnership to launch Manyata initiative improving quality of maternity care in private facilities across India through standardized training and certification programs.
- Ferring PharmaceuticalscoreMerck, Ferring Pharmaceuticals, and WHO collaborated to advance heat-stable carbetocin to prevent excessive bleeding after childbirth (postpartum hemorrhage). Carbetocin remains stable at room temperature unlike oxytocin, addressing cold chain challenges in low-resource settings.
- Pledge Guarantee for HealthminorInnovative financing partnership leveraging private sector funding to speed delivery and access to life-saving health supplies including contraceptives, bed nets, and medicines. Merck and other suppliers provide up-front price discounts to aid recipients.
- Saving Mothers, Giving Life PartnershipcorePublic-private partnership focusing on helping mothers during labor, delivery, and the first 24 hours following birth. Merck committed more than $200 million to the partnership beginning with programs in Uganda and Zambia.
- PATHcoreMerck for Mothers and PATH collaborated to identify game-changing maternal health technologies, focusing on post-partum hemorrhage (PPH) and preeclampsia - the two leading causes of maternal mortality. Collaboration surfaced heat-stable carbetocin and magnesium sulfate optimization initiatives.
Scale indicators10 records
Recent moves6 records
Expansion highlights5 records
Merck Foundation competitors and assessment
Company assessmentDirect peers
- Amgen: Amgen is a leading biologic-products manufacturer with an oncology, inflammation, and cardiovascular portfolio, competing with Merck in biosimilars, hematology, and inflammation — making it a peer in the biologics manufacturing and specialty-pharma segments.
- Roche: Roche is a top-three oncology competitor with a parallel PD-L1 franchise (Tecentriq) directly challenging KEYTRUDA, plus a large diagnostics arm and a vaccine/infectious-disease business that mirrors Merck's therapeutic breadth.
- Sanofi: Sanofi competes across vaccines (Fluzone, pediatric combinations), specialty care, and rare disease, with Dupixent as a flagship immunology asset. Its vaccines and specialty-pharma mix directly mirrors Merck's portfolio structure.
- GSK: GSK is a direct peer in vaccines (Shingrix, Bexsero, Cervarix competing with GARDASIL 9), specialty/HIV medicines, and respiratory disease — making it the closest vaccine-to-vaccine peer to Merck's vaccine franchise.
- Pfizer: Pfizer is a global biopharmaceutical major with overlapping therapeutic areas including oncology, vaccines (including COVID-19 and pneumococcal via Prevnar), infectious diseases, and cardiometabolic therapies — directly comparable to Merck's diversified prescription-pharma and vaccine franchises.
- AstraZeneca: AstraZeneca competes with Merck across oncology (Imfinzi in immuno-oncology, Tagrisso, Lynparza), vaccines (including COVID partnerships), and rare/cardiovascular disease, with a comparable global commercial footprint and pipeline depth.
- Bristol-Myers Squibb: BMS is the most direct immuno-oncology peer via Opdivo (nivolumab), the principal PD-1 competitor to KEYTRUDA, and also competes in hematology, cardiovascular, and immunology — directly overlapping Merck's oncology and specialty-pharma core.
- Eli Lilly: Lilly competes with Merck in oncology, diabetes (parallel to JANUVIA), and immunology, with a rapidly growing cardiometabolic and obesity franchise. Comparable R&D intensity and global commercialization scale make it a relevant large-cap pharma peer.
- Novartis: Novartis is a focused biopharmaceutical peer overlapping with Merck in oncology, cardiometabolic disease (Entresto in heart failure parallels Merck's VERQUVO), and immunology — operating with a similarly diversified specialty-pharma business model.
- Johnson & Johnson: J&J's Innovative Medicine segment competes directly with Merck in oncology, immunology, and infectious disease, while J&J's MedTech and consumer health add adjacent breadth — making it a like-for-like diversified biopharmaceutical peer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Merck Foundation social profiles
Digital presenceMerck Foundation financial estimates
Financial estimateRevenue estimate
Valuation estimate
Merck Foundation leadership team
Management profileNumber of profiles
Profiles9 records
Merck Foundation subsidiaries and ownership
Company hierarchySubsidiaries1 record
Merck Foundation funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Merck Foundation M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Merck Foundation
What does Merck Foundation do?
Merck & Co., Inc. is a research-intensive biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines, vaccines, and animal health products across oncology, infectious diseases, vaccines, cardiometabolic diseases, immunology, and rare diseases. The company's flagship products include KEYTRUDA (pembrolizumab), GARDASIL 9, CAPVAXIVE, LAGEVRIO, and WINREVAIR. It also runs the Merck for Mothers global initiative to end preventable maternal deaths.
Is Merck Foundation a public or private company?
Merck Foundation is a public company. It is classified as public and is currently operating.
When was Merck Foundation founded?
Merck Foundation was founded in 1891.
Where is Merck Foundation based?
Merck Foundation is headquartered in Rahway, United States, in the North America region.
How does Merck Foundation make money?
One revenue line is on record: pharmaceutical Products.
Who are Merck Foundation's main competitors?
Direct peers on record are Amgen, Roche, Sanofi, GSK, Pfizer, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Novartis and Johnson & Johnson.
Does Merck Foundation have an API?
No public API is recorded for Merck Foundation.
What industry is Merck Foundation in?
Merck Foundation's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of BPAGABAO, Monitoring, Evaluation, Research & Learning (MERL). Its NAICS code is 325414 and its SIC code is 2836.